The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

orexigen.com

Founded Year

2002

Stage

Asset Sale | AssetsPurchased

Total Raised

$76M

About Orexigen Therapeutics

Orexigen Therapeutics, based in San Diego, California, is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system (CNS), disorders, with an initial focus on obesity. The Company combines individual generic drugs that have previously received regulatory approval for other indications and, thus, have established post-marketing safety records. It screens these drugs for synergistic CNS activity and combines them into new product candidates. The Company tests combinations of individual generic drugs in its product candidates in an effort to demonstrate adequate efficacy and safety for potential regulatory approval and have not received regulatory approval of any product candidate. Its lead combination product candidates targeted for obesity are Contrave, which is in a Phase III clinical trial, and Empatic, which is in a Phase IIb clinical trial.

Orexigen Therapeutics Headquarter Location

3344 North Torrey Pines Court Suite 200

La Jolla, California, 92037,

United States

+1 858 875 8600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Orexigen Therapeutics Patents

Orexigen Therapeutics has filed 35 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Obesity
  • Phenols
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/1/2017

5/10/2022

Diabetes, Obesity, Abdomen, Syndromes, Rare diseases

Grant

Application Date

3/1/2017

Grant Date

5/10/2022

Title

Related Topics

Diabetes, Obesity, Abdomen, Syndromes, Rare diseases

Status

Grant

Latest Orexigen Therapeutics News

Obesity Management Market Worth Observing Growth Top Key Player- F Hoffmann La Roche Ltd, GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc.

Jun 14, 2021

Search jobs 14-Jun-2021 Obesity Management Market Worth Observing Growth Top Key Player- F Hoffmann La Roche Ltd, GlaxoSmithKline plc., Orexigen Therapeutics, Inc., Arena Pharmaceuticals, Inc. The alarming rise in severe lifestyle diseases such as cardiovascular diseases, diabetes, and hypertension is commonly attributed to improper dietary habits and poor weight management. As a result, various health organizations have introduced detailed obesity management guidelines, which provide consumers information about the consumption of  obesity management drugs . Growing consumer awareness about nutraceuticals that accelerate weight loss is expected to boost sales of obesity management drugs such as Bupropion and Naltrexone in the coming years. However, a mounting number of consumers believing in natural ways to promote weight loss may impact growth prospects of the obesity management market in the coming years. Obesity is one of the most evil scourges of our modern day sedentary lifestyle. It is extremely common in certain countries in the developed world and has even begun spreading its tentacles into developing countries. In our report, ‘Obesity Management Market: Global Industry Analysis and Opportunity Assessment 2017–2027’, we at Future Market Insights have taken an in-depth look at the global obesity management market as these devices will prove invaluable in tackling the pressing health challenges the globe faces today. With the help of several important metrics, our analysts have given their expert opinion on current and future trends that can be reasonably assumed to occur in the global obesity management market. Request a Sample of this Report @  https://www.futuremarketinsights.com/reports/sample/rep-gb-587 The global obesity management market report begins with an executive summary that gives a succinct yet comprehensive first glance at the global obesity management market. The executive summary includes the global obesity management market size by region for both the years 2017 and 2027, market share and the market value by region, treatment type and distribution channel type. All of these have been provided in an easy-to-understand, attractive graphical format for our readers’ convenience. The executive summary also includes a market approach to be adopted, the major segment and countries or regions to target with a differentiating strategy to succeed with flying colours in the global obesity management market. The executive summary is complemented by an introduction to the global obesity management market where we have given a lucid definition of obesity with a few relevant statistics that reveal how much of a challenge obesity truly is on a global scale. We have relied on data from the World Health Organization as an authoritative source of information. The next section of the global obesity management market report focusses on the market analysis. This is where have touched upon the global obesity management market size and the Y-o-Y growth that can be anticipated over the duration of the forecast period, along with the absolute dollar opportunity that can be tapped. A few of the key takeaways are mentioned below the graphs for your quick perusal, which we would highly recommend you to glance at while referring to this section. To understand the global obesity management market, it would be extremely helpful to observe the overall market dynamics beforehand and that is the precise purpose of this section of the global obesity management market report. We have highlighted the macro-economic factors that can have an impact on the global obesity management market, the drivers that can boost the market from both the demand as well as the supply side, along with the restraints that could impede market growth. The trends and opportunities that key stakeholders can expect in the global obesity management market, the relevance and impact of certain forecast factors and the scenario forecast provide a holistic approach to the global obesity management market. The guidelines laid down by relevant regulatory bodies have to be extremely stringent and of the highest standard as any mistake or negligence could prove very costly and could even result in loss of life. The regulations of the U.S FDA and the European Medicine Agency have been detailed in the report. In addition to this, we have briefly spoken about the drugs that are in the pipeline in the global obesity management market. An epidemiology analysis concludes this vital section of the global obesity management market report. In the market analysis and forecast scenario section, we have studied the global obesity management market on the basis of its taxonomy. The Basis Point Share analysis, Y-o-Y growth projections, the market value forecast and the market attractiveness for the drug type, surgery type and distribution channels is mentioned. This can be beneficial for any potential stakeholder who wishes to selectively target certain sections of the global obesity management market. We have divided the global obesity management market into seven regions. Each region has its own dedicated section, where we have detailed the basis point share and Y-o-Y growth projections at a regional level. The market value forecast for the most important countries can assist potential market entrants decide which part of the global obesity management market they wish to focus their resources on. By Treatment Type MEA Along with the regional analysis, it would be advisable to look at what the competition has planned to formulate your own approach in the global obesity management market. We have profiled six renowned companies actively involved in the global obesity management market towards this objective. The company details, key financials, product overview, revenue growth, operating margins and industry classification codes provide you with all the information that you could possibly need. A SWOT analysis and major developments pertaining to the competition completes this critical section of the global obesity management market report. Request for Report Ask A Question @  https://www.futuremarketinsights.com/ask-question/rep-gb-587 Research Methodology The research methodology developed by Future Market Insights is easily one of the best in the industry. Our analysts begin by conducting extensive primary and secondary research to gather adequate data pertaining to the global obesity management market. Data so obtained is validated using the triangulation method. The final data is then thoroughly scrutinised using advanced, proprietary tools to obtain the necessary insights into the global obesity management market. Explore Wide-ranging Coverage of FMI’s HealthcareLandscape Mammalian Transient Protein Expression Market  –The mammalian transient protein expression market has reflected steady growthon the back of growing demand from the biomedicine sector. Efforts into vaccinedevelopment continue to create possibilities for new opportunities. In Vitro Fertilization Banking Services Market  –According to the Centers for Disease Control and Prevention (CDC), about 10% ofwomen in the United States between ages 15 to 44 years have infertility whilethe rate of male infertility is 4.5-6% in North America. Cryopreservation for In-vitro Fertilization (IVF) Market  –According to analysis by Future Market Insights (FMI), cryopreservationfor IVF market surpassed a valuation of US$ 339 million in 2019. Themarket is set to reflect an impressive 10.2% CAGR through 2030. About FMI        Future Market Insights (FMI) is a leading provider of marketintelligence and consulting services, serving clients in over 150countries. FMI  isheadquartered in Dubai, the global financial capital, and has delivery centersin the U.S. and India. FMI’s latest  marketresearch reports  and industry analysis help businesses navigatechallenges and make critical decisions with confidence and clarity amidstbreakneck competition. Our customized and syndicated market research reportsdeliver actionable insights that drive sustainable growth. A team of expert-ledanalysts at FMI continuously tracks emerging trends and events in a broad rangeof industries to ensure that our clients prepare for the evolving needs oftheir consumers. ContactUs

  • When was Orexigen Therapeutics founded?

    Orexigen Therapeutics was founded in 2002.

  • Where is Orexigen Therapeutics's headquarters?

    Orexigen Therapeutics's headquarters is located at 3344 North Torrey Pines Court, La Jolla.

  • What is Orexigen Therapeutics's latest funding round?

    Orexigen Therapeutics's latest funding round is Asset Sale.

  • How much did Orexigen Therapeutics raise?

    Orexigen Therapeutics raised a total of $76M.

  • Who are the investors of Orexigen Therapeutics?

    Investors of Orexigen Therapeutics include Nalpropion Pharmaceuticals, Kleiner Perkins Caufield & Byers, Domain Associates, Sofinnova Ventures, Scale Venture Partners and 7 more.

  • Who are Orexigen Therapeutics's competitors?

    Competitors of Orexigen Therapeutics include Titan Pharmaceuticals, Gelesis, Euroclone SpA, BioMarck Pharmaceuticals, FORUM Pharmaceuticals, XenoPort, Telormedix, YM BioSciences, BrainCells, Allos Therapeutics and 22 more.

You May Also Like

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

A
AngioChem

AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.

T
Telormedix

Telormedix is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company's lead product, TMX-101, is currently in a Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder. In addition, Telormedix is developing novel TLR7-targeted agonists. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Telormedix also has a pipeline of programs for inflammatory and autoimmune diseases, which includes TMX-302, a TLR7-binding small molecule showing anti-inflammatory properties in vivo.

D
Dynogen Pharmaceuticals

Dynogen is a biopharmaceutical company developing drugs for gastrointestinal (GI) and genitourinary (GU) disorders, including irritable bowel syndrome (IBS) and overactive bladder (OAB). Dynogen focuses on compounds that have previously been in the clinic and therefore have known safety and pharmacokinetic profiles.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.